{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T23:36:59Z","timestamp":1772840219141,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T00:00:00Z","timestamp":1692057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T00:00:00Z","timestamp":1692057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>Lupus nephritis is a prevalent renal manifestation of systemic lupus erythematosus (SLE) and represents a significant cause of morbidity and mortality associated with the disease. This study endeavors to undertake a meticulous bibliometric analysis of LN publications to comprehend the research hotspots and future directions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The literature on LN was acquired from the Web of Science Core Collection (WoSCC). Co-occurrence and cooperative relationship analysis of authors, institutions, countries, journals, references and keywords in the publication was performed through CiteSpace, VOSviewer and a bibliometric online analysis platform. The knowledge graphs were created, and clustering and emergence analyses were performed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>According to the search strategy, a total of 2077 publications related to lupus nephritis (LN) have been identified, with China being the largest contributor globally. The Ohio State University emerged as the most prolific institution. Lupus is the most cited and published journal. Jan J Weening and Brad Rovin were the most prolific and cocited authors. The current research focus revolved around the \u201cnirp3 inflammasome,\u201d \u201cbiomarker,\u201d and \u201cvoclosporin\u201d. \u201cinternational society,\u201d \u201cthrombotic microangiopathy (TMA),\u201d and \u201cpathway\u201d were identified to be future research hotpots by keyword burst analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This bibliometric analysis summarizes for the first time the progress of LN research (2012\u20132022), and qualitatively and quantitatively evaluates the bibliometric information of LN research. There has been a steady increase in the scientific literature on LN over the past 11\u00a0years, with an average growth rate of 7.27%. In this field, researchers are primarily based in China and the United States. The pathogenic mechanisms, management strategies and prognostic outcomes of LN are acknowledged as prospective research hotspots. Bibliometrically, the research status and trends of LN publications may greatly assist and be a significant reference for future research in the area.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11255-023-03715-w","type":"journal-article","created":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T14:02:43Z","timestamp":1692108163000},"page":"781-794","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Research trends and frontiers in lupus nephritis: a bibliometric analysis from 2012 to 2022"],"prefix":"10.1007","volume":"56","author":[{"given":"Jiaping","family":"Qi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoyu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingchen","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5443-3675","authenticated-orcid":false,"given":"Zhenhua","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,15]]},"reference":[{"issue":"1","key":"3715_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","volume":"6","author":"HJ Anders","year":"2020","unstructured":"Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C (2020) Lupus nephritis. Nat Rev Dis Primers 6(1):7","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"3715_CR2","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1097\/01.ASN.0000140218.77174.0A","volume":"15","author":"FA Houssiau","year":"2004","unstructured":"Houssiau FA (2004) Management of lupus nephritis: an update. J Am Soc Nephrol 15(10):2694\u20132704","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"3715_CR3","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.1002\/art.20666","volume":"50","author":"FA Houssiau","year":"2004","unstructured":"Houssiau FA, Vasconcelos C, D\u2019Cruz D, Sebastiani GD, de Ramon GE, Danieli MG et al (2004) Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial: early response to treatment predicts good outcome in lupus nephritis. Arthritis Rheum 50(12):3934\u20133940","journal-title":"Arthritis Rheum"},{"issue":"5","key":"3715_CR4","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1177\/0961203308090029","volume":"17","author":"F Houssiau","year":"2008","unstructured":"Houssiau F, Ginzler E (2008) Current treatment of lupus nephritis. Lupus 17(5):426\u2013430","journal-title":"Lupus"},{"issue":"9","key":"3715_CR5","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","volume":"17","author":"MRW Barber","year":"2021","unstructured":"Barber MRW, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow NY et al (2021) Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol 17(9):515\u2013532","journal-title":"Nat Rev Rheumatol"},{"key":"3715_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102871","volume":"132","author":"C Yu","year":"2022","unstructured":"Yu C, Li P, Dang X, Zhang X, Mao Y, Chen X (2022) Lupus nephritis: new progress in diagnosis and treatment. J Autoimmun 132:102871","journal-title":"J Autoimmun"},{"issue":"1","key":"3715_CR7","doi-asserted-by":"publisher","first-page":"17088","DOI":"10.1038\/nrdp.2017.88","volume":"3","author":"P Romagnani","year":"2017","unstructured":"Romagnani P, Remuzzi G, Glassock R, Levin A, Jager KJ, Tonelli M et al (2017) Chronic kidney disease. Nat Rev Dis Primers 3(1):17088","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"3715_CR8","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/art.40724","volume":"71","author":"M Mackay","year":"2019","unstructured":"Mackay M, Dall\u2019Era M, Fishbein J, Kalunian K, Lesser M, Sanchez-Guerrero J et al (2019) Establishing surrogate kidney end points for lupus nephritis clinical trials: development and validation of a novel approach to predict future kidney outcomes. Arthritis Rheumatol 71(3):411\u2013419","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"3715_CR9","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.autrev.2019.05.011","volume":"18","author":"A Mageau","year":"2019","unstructured":"Mageau A, Timsit JF, Perrozziello A, Ruckly S, Dupuis C, Bouadma L et al (2019) The burden of chronic kidney disease in systemic lupus erythematosus: a nationwide epidemiologic study. Autoimmun Rev 18(7):733\u2013737","journal-title":"Autoimmun Rev"},{"key":"3715_CR10","doi-asserted-by":"publisher","unstructured":"Tunnicliffe DJ, Palmer SC, Henderson L, Masson P, Craig JC, Tong A et al (2018) Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Kidney and Transplant Group, editor. Cochrane Database of Systematic Reviews [Internet]. 2018 Jun 29 [Cited 3 Mar 2023]; 2018(6). Available from: https:\/\/doi.org\/10.1002\/14651858.CD002922.pub4","DOI":"10.1002\/14651858.CD002922.pub4"},{"key":"3715_CR11","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.2147\/JPR.S258739","volume":"13","author":"R Li","year":"2020","unstructured":"Li R, Sun J, Hu H, Zhang Q, Sun R, Zhou S et al (2020) Research trends of acupuncture therapy on knee osteoarthritis from 2010 to 2019: a bibliometric analysis. JPR 13:1901\u20131913","journal-title":"JPR"},{"issue":"12","key":"3715_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2021.759347","volume":"17","author":"H Luo","year":"2021","unstructured":"Luo H, Cai Z, Huang Y, Song J, Ma Q, Yang X et al (2021) Study on pain catastrophizing from 2010 to 2020: a bibliometric analysis via citespace. Front Psychol 17(12):759347","journal-title":"Front Psychol"},{"issue":"13","key":"3715_CR13","doi-asserted-by":"publisher","first-page":"1035229","DOI":"10.3389\/fphar.2022.1035229","volume":"1","author":"T Wu","year":"2022","unstructured":"Wu T, Huang W, Qi J, Li Y, Zhang Y, Jiang H et al (2022) Research trends and frontiers on antiphospholipid syndrome: A 10-year bibliometric analysis (2012\u20132021). Front Pharmacol 1(13):1035229","journal-title":"Front Pharmacol"},{"issue":"12","key":"3715_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.731933","volume":"18","author":"D Ma","year":"2021","unstructured":"Ma D, Yang B, Guan B, Song L, Liu Q, Fan Y et al (2021) A Bibliometric analysis of pyroptosis from 2001 to 2021. Front Immunol 18(12):731933","journal-title":"Front Immunol"},{"issue":"2","key":"3715_CR15","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","volume":"84","author":"NJ van Eck","year":"2010","unstructured":"van Eck NJ, Waltman L (2010) Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics 84(2):523\u2013538","journal-title":"Scientometrics"},{"issue":"5","key":"3715_CR16","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2215\/CJN.05780616","volume":"12","author":"S Almaani","year":"2017","unstructured":"Almaani S, Meara A, Rovin BH (2017) Update on lupus nephritis. CJASN 12(5):825\u2013835","journal-title":"CJASN"},{"issue":"4","key":"3715_CR17","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","volume":"93","author":"IM Bajema","year":"2018","unstructured":"Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT et al (2018) Revision of the international society of nephrology\/renal pathology society classification for lupus nephritis: clarification of definitions, and modified national institutes of health activity and chronicity indices. Kidney Int 93(4):789\u2013796","journal-title":"Kidney Int"},{"issue":"6","key":"3715_CR18","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/acr.21664","volume":"64","author":"BH Hahn","year":"2012","unstructured":"Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, FitzGerald JD et al (2012) American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 64(6):797\u2013808","journal-title":"Arthritis Care Res"},{"issue":"5","key":"3715_CR19","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1681\/ASN.2008101028","volume":"20","author":"GB Appel","year":"2009","unstructured":"Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D et al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20(5):1103\u20131112","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"3715_CR20","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","volume":"71","author":"GK Bertsias","year":"2012","unstructured":"Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JHM et al (2012) Joint European league against rheumatism and european renal association-european dialysis and transplant association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71(11):1771\u20131782","journal-title":"Ann Rheum Dis"},{"key":"3715_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/CPAA.S255789","volume":"12","author":"Y Li","year":"2020","unstructured":"Li Y, Palmisano M, Sun D, Zhou S (2020) Pharmacokinetic disposition difference between cyclosporine and voclosporin drives their distinct efficacy and safety profiles in clinical studies. CPAA 12:83\u201396","journal-title":"CPAA"},{"issue":"5","key":"3715_CR22","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s40265-021-01488-z","volume":"81","author":"YA Heo","year":"2021","unstructured":"Heo YA (2021) Voclosporin: first approval. Drugs 81(5):605\u2013610","journal-title":"Drugs"},{"issue":"10289","key":"3715_CR23","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","volume":"397","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J et al (2021) Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet 397(10289):2070\u20132080","journal-title":"The Lancet"},{"issue":"3","key":"3715_CR24","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.gpb.2013.05.003","volume":"11","author":"Y Li","year":"2013","unstructured":"Li Y, Fang X, Li QZ (2013) Biomarker profiling for lupus nephritis. Genomics Proteomics Bioinformatics 11(3):158\u2013165","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"6","key":"3715_CR25","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/art.39594","volume":"68","author":"MG Tektonidou","year":"2016","unstructured":"Tektonidou MG, Dasgupta A, Ward MM (2016) Risk of end-stage renal disease in patients with lupus nephritis, 1971\u20132015: a systematic review and bayesian meta-analysis: ESRD RISK IN LUPUS NEPHRITIS. Arthritis Rheumatol 68(6):1432\u20131441","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"3715_CR26","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/rheumatology\/kev311","volume":"55","author":"JG Hanly","year":"2016","unstructured":"Hanly JG, O\u2019Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C et al (2016) The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology 55(2):252\u2013262","journal-title":"Rheumatology"},{"issue":"7","key":"3715_CR27","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41590-019-0398-x","volume":"20","author":"A Arazi","year":"2019","unstructured":"The Accelerating Medicines Partnership in SLE network, Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y et al (2019) The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol 20(7):902\u2013914","journal-title":"Nat Immunol"},{"issue":"6","key":"3715_CR28","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN et al (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78(6):736\u2013745","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"3715_CR29","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nrneph.2017.85","volume":"13","author":"F Yu","year":"2017","unstructured":"Yu F, Haas M, Glassock R, Zhao MH (2017) Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol 13(8):483\u2013495","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"3715_CR30","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/BOR.0b013e328354c877","volume":"24","author":"OP Kulkarni","year":"2012","unstructured":"Kulkarni OP, Anders HJ, Lupus nephritis (2012) How latest insights into its pathogenesis promote novel therapies. Curr Opin Rheumatol 24(5):457\u2013465","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"3715_CR31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.7326\/M14-1030","volume":"162","author":"Z Liu","year":"2015","unstructured":"Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z et al (2015) Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 162(1):18\u201326","journal-title":"Ann Intern Med"},{"issue":"2","key":"3715_CR32","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.kint.2017.08.031","volume":"93","author":"J Fu","year":"2018","unstructured":"Fu J, Wang Z, Lee K, Wei C, Liu Z, Zhang M et al (2018) Transcriptomic analysis uncovers novel synergistic mechanisms in combination therapy for lupus nephritis. Kidney Int 93(2):416\u2013429","journal-title":"Kidney Int"},{"issue":"12","key":"3715_CR33","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1177\/09612033221122148","volume":"31","author":"YH Lee","year":"2022","unstructured":"Lee YH, Song GG (2022) Multitarget therapy versus monotherapy as induction treatment for lupus nephritis: a meta-analysis of randomized controlled trials. Lupus 31(12):1468\u20131476","journal-title":"Lupus"},{"issue":"1","key":"3715_CR34","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/ar4142","volume":"15","author":"D Song","year":"2013","unstructured":"Song D, Wu LH, Wang FM, Yang XW, Zhu D, Chen M et al (2013) The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther 15(1):12","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"3715_CR35","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.3899\/jrheum.180773","volume":"46","author":"C Li","year":"2019","unstructured":"Li C, Yap DYH, Chan G, Wen Y, bing, Li H, Tang C, et al (2019) Clinical outcomes and clinico-pathological correlations in lupus nephritis with kidney biopsy showing thrombotic microangiopathy. J Rheumatol 46(11):1478\u20131484","journal-title":"J Rheumatol"},{"issue":"18","key":"3715_CR36","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s40265-013-0147-7","volume":"73","author":"GM Keating","year":"2013","unstructured":"Keating GM (2013) Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs 73(18):2053\u20132066","journal-title":"Drugs"},{"issue":"3","key":"3715_CR37","first-page":"169","volume":"15","author":"X Chen","year":"2021","unstructured":"Chen X, Cheng W, Wang G, Qi Y, Xiao J, Wang X et al (2021) Clinical characteristics and prognosis of renal thrombotic microangiopathy in lupus nephritis. Iran J Kidney Dis 15(3):169\u2013176","journal-title":"Iran J Kidney Dis"},{"issue":"1","key":"3715_CR38","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1681\/ASN.2005080868","volume":"17","author":"M J\u00f3zsi","year":"2006","unstructured":"J\u00f3zsi M, Heinen S, Hartmann A, Ostrowicz CW, H\u00e4lbich S, Richter H et al (2006) Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions. JASN 17(1):170\u2013177","journal-title":"JASN"},{"issue":"13","key":"3715_CR39","doi-asserted-by":"publisher","first-page":"1081942","DOI":"10.3389\/fimmu.2022.1081942","volume":"13","author":"B Zhang","year":"2022","unstructured":"Zhang B, Xing G (2022) Thrombotic microangiopathy mediates poor prognosis among lupus nephritis via complement lectin and alternative pathway activation. Front Immunol 13(13):1081942","journal-title":"Front Immunol"},{"key":"3715_CR40","unstructured":"Fan G, Han R, Zhang H, He S, Chen Z (2015) Worldwide research productivity in the field of minimally invasive spine surgery: a 20-year survey of publication activities"},{"key":"3715_CR41","unstructured":"Weening JJ, D\u2019Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB et al The classification of glomerulonephritis in systemic lupus erythematosus revisited"},{"issue":"2","key":"3715_CR42","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1053\/j.ajkd.2019.10.017","volume":"76","author":"SV Parikh","year":"2020","unstructured":"Parikh SV, Almaani S, Brodsky S, Rovin BH (2020) Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis 76(2):265\u2013281","journal-title":"Am J Kidney Dis"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03715-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-023-03715-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03715-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T17:12:19Z","timestamp":1706116339000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-023-03715-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,15]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["3715"],"URL":"https:\/\/doi.org\/10.1007\/s11255-023-03715-w","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,15]]},"assertion":[{"value":"15 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}